These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33355290)

  • 1. Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune-Tumor Interactions: Engage, Expand, Enable.
    Fabian KP; Malamas AS; Padget MR; Solocinski K; Wolfson B; Fujii R; Abdul Sater H; Schlom J; Hodge JW
    Cancer Immunol Res; 2021 Feb; 9(2):239-252. PubMed ID: 33355290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve.
    Fabian KP; Padget MR; Fujii R; Schlom J; Hodge JW
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
    Hicks KC; Knudson KM; Lee KL; Hamilton DH; Hodge JW; Figg WD; Ordentlich P; Jones FR; Rabizadeh S; Soon-Shiong P; Schlom J; Gameiro SR
    Clin Cancer Res; 2020 Feb; 26(3):704-716. PubMed ID: 31645354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
    Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
    Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.
    Farsaci B; Higgins JP; Hodge JW
    Int J Cancer; 2012 Apr; 130(8):1948-59. PubMed ID: 21633954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
    Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
    J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation Augments the Local Anti-Tumor Effect of
    Pieper AA; Zangl LM; Speigelman DV; Feils AS; Hoefges A; Jagodinsky JC; Felder MA; Tsarovsky NW; Arthur IS; Brown RJ; Birstler J; Le T; Carlson PM; Bates AM; Hank JA; Rakhmilevich AL; Erbe AK; Sondel PM; Patel RB; Morris ZS
    Front Immunol; 2021; 12():763888. PubMed ID: 34868010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy.
    Lee KL; Benz SC; Hicks KC; Nguyen A; Gameiro SR; Palena C; Sanborn JZ; Su Z; Ordentlich P; Rohlin L; Lee JH; Rabizadeh S; Soon-Shiong P; Niazi K; Schlom J; Hamilton DH
    Cancer Immunol Res; 2019 Aug; 7(8):1359-1370. PubMed ID: 31292145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
    Redmond WL; Linch SN; Kasiewicz MJ
    Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine.
    Abrams SI; Hodge JW; McLaughlin JP; Steinberg SM; Kantor JA; Schlom J
    J Immunother; 1997 Jan; 20(1):48-59. PubMed ID: 9101413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models.
    Franks SE; Fabian KP; Santiago-Sánchez G; Wolfson B; Hodge JW
    Oncoimmunology; 2022; 11(1):2124666. PubMed ID: 36211806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.
    Fernandez MF; Qiao G; Tulla K; Prabhakar BS; Maker AV
    J Surg Res; 2021 Jul; 263():44-52. PubMed ID: 33631377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
    Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J
    Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
    Hebb JPO; Mosley AR; Vences-Catalán F; Rajasekaran N; Rosén A; Ellmark P; Felsher DW
    Cancer Immunol Immunother; 2018 Jan; 67(1):47-60. PubMed ID: 28905118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.
    Donahue RN; Duncan BB; Fry TJ; Jones B; Bachovchin WW; Kiritsy CP; Lai JH; Wu W; Zhao P; Liu Y; Tsang KY; Hodge JW
    Vaccine; 2014 May; 32(26):3223-31. PubMed ID: 24731809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
    Saha A; Chatterjee SK
    Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.